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Sustained neuroinflammation mediated by resident microglia is recognized as a key pathophysiological contributor to many neurode-
generative diseases, including Parkinson’s disease (PD), but the key molecular signaling events regulating persistent microglial activa-
tion have yet to be clearly defined. In the present study, we examined the role of Fyn, a non-receptor tyrosine kinase, in microglial
activation and neuroinflammatorymechanisms in cell culture and animal models of PD. The well-characterized inflammogens LPS and
TNF rapidly activated Fyn kinase inmicroglia. Immunocytochemical studies revealed that activated Fyn preferentially localized to the
microglial plasma membrane periphery and the nucleus. Furthermore, activated Fyn phosphorylated PKC at tyrosine residue 311,
contributing to an inflammogen-induced increase in its kinase activity. Notably, the Fyn-PKC signaling axis further activated the LPS-
and TNF-induced MAP kinase phosphorylation and activation of the NFB pathway, implying that Fyn is a major upstream regulator
of proinflammatory signaling. Functional studies in microglia isolated from wild-type (Fyn/) and Fyn knock-out (Fyn/) mice
revealed that Fyn is required for proinflammatory responses, including cytokine release as well as iNOS activation. Interestingly, a
prolonged inflammatory insult induced Fyn transcript and protein expression, indicating that Fyn is upregulated during chronic inflam-
matory conditions. Importantly, in vivo studies usingMPTP, LPS, or 6-OHDAmodels revealed a greater attenuation of neuroinflamma-
tory responses in Fyn/ and PKC / mice compared with wild-type mice. Collectively, our data demonstrate that Fyn is a major
upstream signaling mediator of microglial neuroinflammatory processes in PD.
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Introduction
Parkinson’s disease (PD) is a highly prevalent neurodegenerative
disorder and is mainly characterized by the loss of dopaminergic
neurons in the substantia nigra (SN) of the ventralmidbrain region.
Extra nigral lesions and non-motor deficits have recently been rec-
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Significance Statement
Parkinson’s disease (PD) is a complexmultifactorial disease characterizedby the progressive loss ofmidbrain dopamineneurons.
Sustained microglia-mediated neuroinflammation has been recognized as a major pathophysiological contributor to chronic
degenerative processes in PD; however, the keymolecular signalingmechanisms underlyingmicroglial activation are not entirely
clear. Herein, we identified a novel role for the non-receptor tyrosine kinase Fyn in regulating neuroinflammatory responses in
microglia. Our data clearly suggest that the Fyn-PKC signaling axis acts as amajor upstream signalingmediator of the sustained
neuroinflammatory processes in cell culture and animal models of PD. Our finding has important clinical significance to PD
because it identifies Fyn as a potential translational target for intervention of progressive neurodegenerative processes in PD.
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ognized (Chaudhuri et al., 2006; Bohnen et al., 2014). Although the
etiopathogenesis of PD is not known, both environmental insults
and genetic defects have been implicated in its onset. Mutations in
seven disparate genes have been linked to Parkinsonism,which clin-
ically resembles PDwith varying onset and disease progression. Ad-
ditionally, 19 other genes have been hypothesized to have a disease-
causing role (Puschmann, 2013).
The pathophysiology of PD is complex and multifactorial,
with mitochondrial dysfunction, oxidative stress, apoptosis
and proteasomal dysfunction being identified among others as
potential disease mechanisms underlying nigrostriatal dopa-
minergic neuronal degeneration (Przedborski, 2005; Jenner
and Olanow, 2006; Olanow, 2007; Levy et al., 2009). Recently,
a wealth of data from cell culture, animal models and post-
mortem analyses of human PD brains have established
chronic, sustained microglia-mediated neuroinflammation as
being a major event in the delayed and progressive loss of
dopaminergic neurons within the SN (Imamura et al., 2003;
Block et al., 2007; Glass et al., 2010; Tansey and Goldberg,
2010). As the macrophagic cells of the CNS, microglia com-
pose a major component of the brain’s innate immune system.
Under “normal” physiological conditions, they produce anti-
inflammatory and neurotrophic factors to promote neuronal
survival and plasticity (Carson, 2002). However, when they
encounter a potential pathogen, a dead or dying neuron, or
neurotoxic stress, they switch to an “activated” phenotype,
producing proinflammatory cytokines and chemokines, reac-
tive nitrogen species and reactive oxygen species. Activated
microglia may also directly contribute to cell death by phago-
cytizing dopaminergic neurons (Barcia et al., 2012; Virgone-
Carlotta et al., 2013). Thus, the pathophysiology of PD is
accompanied by a sustained proinflammatory microglial re-
sponse that contributes to neuron death, thereby exacerbating
disease progression.
Fyn, a member of the Src family of kinases, is a non-receptor
tyrosine kinase expressed in the brain. The kinase has been shown to
play a role in amyloid-mediated apoptosis in cortical neurons (Lam-
bert et al., 1998), astrocyte migration (Dey et al., 2008), and oligo-
dendrocyte differentiation (Sperber et al., 2001). In the peripheral
immune system,Fynplays a role inmast cell andB-/T-cell activation
(Palacios and Weiss, 2004; Gomez et al., 2005). Fyn was shown to
mediate proinflammatory mediator production in mast cells, mac-
rophages, basophils, as well as in natural killer cells (Rajasekaran et
al., 2013). Fyn was shown to be activated following fibrillar
-amyloid peptide engagement of its receptor CD36, contributing
to activation and migration of primary murine peritoneal macro-
phages andmicroglia (Moore et al., 2002; Stuart et al., 2007), and in
BV2 microglial cells stimulated with the neurotoxic fragment of
prion protein (Kouadir et al., 2012). Recently, we have identified a
proapoptotic Fyn/PKC-mediated signaling pathway that contrib-
utes to oxidative stress-induced cell death in dopaminergic neurons
(Kaul et al., 2005; Saminathan et al., 2011).However, the role of Fyn
in microglial activation and neuroinflammation has never been
studied in PD. Therefore, we sought to characterize the role of the
Fyn-PKC signaling pathway in microglial activation and neuroin-
flammation in cell culture and animal models of PD. The results
from these comprehensive studies reveal that Fyn kinase plays a key
role inmicroglial activationandsustainedneuroinflammation in the
nigral dopaminergic system.
Materials andMethods
Chemicals and reagents. DMEM/F-12, ascorbic acid, RPMI, FBS,
L-glutamine, Hoechst nuclear stain, penicillin, streptomycin, and other
cell culture reagents were purchased from Invitrogen. Recombinant tu-
mor necrosis factor alpha (TNF) was purchased from Peprotech, and
lipopolysaccharide (LPS) (Escherichia coli 0111:B4, endotoxin content
6.6000000 EU/mg), 6-hydroxydopamine (6-OHDA), and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)were purchased from Sigma.
The mouse Fyn antibody was purchased from Thermo Scientific. Anti-
bodies for rabbit Fyn, PKC, p-Y311 PKC, IB, Lamin-B, NOS2
(iNOS), and mouse tubulin were purchased from Santa Cruz Biotech-
nology. Antibodies against rabbit p-Src family kinase Y416 (p-Y416
SFK), native p65, p-p38 MAP kinase, native p38 MAP kinase, p-p44/42
MAP kinase (p-ERK), and native p44/42 MAP kinase (ERK) were pur-
chased fromCell Signaling Technology. The gp91phox antibody was pur-
chased from BD Biosciences. The mouse GFAP antibody was purchased
fromMillipore. The TH antibody was purchased fromMillipore. Mouse
M2 FLAG and -actin antibodies as well as the rabbit -actin antibody
were purchased from Sigma. Rabbit and goat Iba-1 antibodies were pur-
chased fromWako Chemicals and Abcam, respectively. The goat TNF
antibody was purchased from R&D Systems. 32P-ATP was purchased
from PerkinElmer and the histone substrate from Sigma. The Bradford
protein assay kit was purchased from Bio-Rad Laboratories. The dual-
luciferase reporter construct containing 3.1 kb human Fyn promoter
fragment was provided by Dr. Joya Chandra (University of Texas M. D.
AndersonCancer Center, Houston, TX). FLAG-tagged humanwild-type
(WT) Fyn and Y417Amutant Fyn constructs were obtained as described
previously (Kaspar and Jaiswal, 2011).
Animal studies. The Fyn/ and PKC/mice used in these studies
were bred in our animal facility. Fyn/ mice were originally obtained
from Dr. Dorit Ron’s laboratory at the University of California, San
Francisco, and are available from The Jackson Laboratory (stock
#002271). PKC/mice were obtained originally fromDr. Keiichi Na-
kayama’s laboratory (Division of Cell Biology, Department ofMolecular
andCellular Biology,Medical Institute of Bioregulation, KyushuUniver-
sity, Fukuoka, Japan). Wild-type (Fyn/ and PKC/), PKC/,
and Fyn/ mice were housed under standard conditions of constant
temperature (22 1°C), humidity (relative, 30%), and a 12 h light cycle
with food and water provided ad libitum. Six- to eight-week-old male
micewere used for all studies. Thewell-characterized acuteMPTPmouse
model of PD (Wu et al., 2003; Przedborski et al., 2004; Kim et al., 2007;
Hu et al., 2008) was primarily used for neuroinflammation studies. The
mice from the MPTP treatment group received four intraperitoneal in-
jections of MPTP-HCl (18 mg/kg free-base) dissolved in saline at 2 h
intervals. Mice were killed 24 h after the last injection. The nigral neuro-
inflammatory response was also studied using the systemic LPS injection
model (Qin et al., 2007), which induces chronic neuroinflammation and
progressive dopaminergic degeneration inmice. A single injection of LPS
(5 mg/kg, i.p.) was delivered to wild-type, Fyn/, and PKC/mice.
Mice were killed 3 h later. Control groups for both MPTP and LPS
received equivolume injections of saline. We injected 2 l of 6-OHDA,
diluted at a concentration of 5 g/l in 0.02% ascorbic acid, into the left
striatum (0.2 l/min) using the Angle 2 stereotaxic apparatus (Leica
Biosystems). The coordinates relative to bregma were as follows: 0.7 mm
anteroposterior, 2mm lateral, and 2.4mmventral. The contralateral side
was either not injected or injected with 2 l of 0.02% ascorbic acid
diluted in sterile PBS as a negative control. All animal procedures were
approved by the Iowa StateUniversity Institutional Animal Care andUse
Committee.
Primarymicroglial cultures and treatments.Primarymicroglial cultures
were prepared from wild-type, Fyn/, and PKC/ postnatal day 1
(P1) mouse pups as described previously (Gordon et al., 2011). Briefly,
mouse brains were harvested, meninges removed, and then placed in
DMEM-F12 supplemented with 10% heat-inactivated FBS, 50 IU/ml
penicillin, 50g/ml streptomycin, 2 mM L-glutamine, 100M nonessen-
tial amino acids, and 2 mM sodium pyruvate. Brain tissues were then
incubated in 0.25% trypsin-EDTA for 30 min with gentle agitation. The
trypsin reaction was stopped by adding double the volume of DMEM/
F12 complete medium and then washing brain tissues three times. Tis-
sueswere then triturated gently to prepare a single-cell suspension,which
was then passed through a 70 m nylon mesh cell strainer to remove
tissue debris and aggregates. The cell suspension was then made up in
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DMEM/F12 complete medium and seeded into T-75 flasks, which were
incubated in humidified 5%CO2 at 37°C. Themediumwas changed after
5–6 d, and themixed glial cells were grown to confluence.Microglial cells
were separated from confluent mixed glial cultures by differential adher-
ence and magnetic separation to97% purity and then were allowed to
recover for 48 h after plating. Primary microglia were treated in DMEM/
F12 complete medium containing 2% FBS. For signaling experiments,
the protocol used by Stuart (2007) was used with a small modification.
For this, the primary microglial cells were kept in 2% DMEM/F12 com-
plete medium for 5 h at 37°C before treatment. The microglial cells were
treated with 100–200 ng/ml LPS and 10–30 ng/ml TNF for durations
sampled at prespecified time points. We selected the LPS doses used in
this study based on previous studies in which stimulation of cultured
primary mouse microglia with 100 and 200 ng/ml LPS resulted in signif-
icant microglial activation (Haynes et al., 2006; Crotti et al., 2014; Lee et
al., 2014).
siRNAs and transfections of microglia. Transient transfections of pri-
mary microglia with Fyn promoter reporter were performed using Lipo-
fectamine LTX and Plus Reagent according to the manufacturer’s
protocol. Primary microglia were plated at 0.75  106 cells/well in 12-
well plates 1 d before transfection.We transiently transfected 3g of Fyn
promoter construct. Cells were treated 24 h after transfection with or
without 200 ng/ml of LPS for 12 h and then lysed. Luciferase activity was
measured using a Dual-luciferase assay kit (Promega) on a Synergy 2
multimode microplate reader (BioTek Instruments). Firefly luciferase
luminescence values were used to normalize Renilla luciferase lumines-
cence values. The predesigned, on-target plus SMARTpool Fyn siRNA (a
combination of four siRNAs, catalog #LQ-040112-00-0002) and scram-
bled siRNA (catalog #D-001210-03-05) were purchased from Dharma-
con. We performed siRNA transfections in primary mouse microglial
cells with Lipofectamine 3000 reagent according to the manufacturer’s
protocol. Briefly, primary microglia were plated at 2 106 cells/well in
6-well plates 1 d before transfection. For each well, 300 pmol of Fyn
siRNA pool (75 pmol each) or an equal amount of scrambled siRNA
mixed with 5 l of Lipofectamine 3000 was added to the cells. Seventy-
two hours after the initial transfection, cells were analyzed by Western
blotting to confirm the extent of Fyn knockdown or treated with LPS
(200 ng/ml) for 24 h further, after which cytokine content was analyzed
by Luminex bioassay.
Transfection of BV2 microglia with WT Fyn-FLAG, Y417A Fyn-
FLAG, and Empty vector pcDNA3.1 constructs was performed using the
Amaxa Nucleofector kit (Lonza). Briefly, BV2 cells were resuspended in
transfection buffer (solution 1: 400 M ATP-disodium, Sigma A7699;
600 M MgCl2-6H2O in water; solution 2: 100 M KH2PO4, 20 M
NaHCO3, 5M glucose in water) to a final concentration of 3 10
6 cells
per 100l andmixed with the respective vector; 5g of vector DNAwas
used per transfection.
Immunohistochemistry and immunofluorescence studies. Immunohis-
tochemistry was performed on sections from the SN and other brain
regions of interest as described previously (Jin et al., 2011b; Ghosh et al.,
2013). Briefly, mice were anesthetized with a mixture of 100 mg/kg ket-
amine and 10 mg/kg xylazine and then perfused transcardially with
freshly prepared 4% PFA. Extracted brains were postfixed in 4% PFA for
48 h, and 30 m sections were cut using a freezing microtome (Leica
Microsystems). Antigen retrieval was performed in citrate buffer (10mM
sodium citrate, pH 8.5) for 30 min at 90°C. Sections were then washed
several times in PBS and blocked with PBS containing 2% BSA, 0.2%
TritonX-100, and 0.05%Tween 20 for 1 h at room temperature. Sections
were then incubated with primary antibodies overnight at 4°C and
washed 7 times in PBS on a Belly Dancer shaker (SPI Supplies). The
sections were incubatedwith Alexa dye-conjugated secondary antibodies
for 75 min at room temperature, and their cell nuclei were stained with
Hoechst dye. Sections were mounted on slides using Prolong antifade
gold mounting medium (Invitrogen) according to the manufacturer’s
instructions. Samples were visualized using an inverted fluorescence mi-
croscope (Nikon TE-2000U), and images were captured using a Spot
digital camera (Diagnostic Instruments).
Immunofluorescence studies in primary microglia were performed
according to previously published protocols with some modifications
(Gordon et al., 2011). Briefly, microglial cells were grown on poly-D-
lysine-coated coverslips and treated 48 h later. At the end of treatments,
cells were fixed with 4% PFA, washed in PBS, and incubated in blocking
buffer (PBS containing 2% BSA, 0.5% Triton X-100 and 0.05% Tween
20) for 1 h at room temperature. The coverslips were then incubated
overnight at 4°C with respective primary antibodies diluted in PBS con-
taining 2% BSA. Samples were then washed several times in PBS and
incubated with Alexa-488 and -555 dye-conjugated secondary antibod-
ies. The nuclei were labeledwithHoechst stain (10g/ml), and coverslips
were mounted with Fluoromount medium (Sigma-Aldrich) on glass
slides for visualization. Quantification of the number of microglial/as-
troglial cells obtained after separation was accomplished using JACoP, a
downloadable ImageJ plugin from Fabrice P. Cordelie`res and Susanne
Bolte. Original Hoechst or antibody TIFF files were converted into 8-bit
black-and-white images, and a colocalization image was generated.
Counting of Hoechst-positive and Iba-1Hoechst-positive cells was
done using the cell counter function of the default “Analyze” plugin in
ImageJ.
Confocal imaging and Z-stack image acquisition and analysis. Confocal
imaging was performed at the Iowa State UniversityMicroscopy Facility,
using a Leica DMIRE2 confocal microscope with the 63 and 43 oil
objectives and Leica Confocal Software. One optical series covered 11–13
optical slices of 0.5m thickness each.Microglial neuronal contact iden-
tification and quantification were performed by counting the number of
colocalizations of the two markers, with THmarked red by anti-555 and
Iba-1 marked green by anti-488 using the methodology described by
Barcia et al. (2012). The Imaris software was used to analyze the Z-stack
images for contact identification. The surface reconstruction wizard in
the Imaris software was used to make 3D reconstructions of stacks
for easier viewing of microglial-dopaminergic contacts and surface
topology.
qRT-PCR. RNA isolation from primary microglial cells and brain tis-
sue samples was performed using the Absolutely RNAMiniprep kit, and
then 1 g total of isolated RNA was used for reverse transcription with
the AffinityScript qPCR cDNA synthesis system (Agilent Technologies)
according to the manufacturer’s instructions. Quantitative SYBR Green
PCR assays for gene expression were performed using the RT2 SYBR
Green Master Mix with prevalidated primers (SA Biosciences). Catalog
numbers of the primers were as follows: Fyn, PPM04015A; pro-IL1,
PPM03109E; and TNF, PPM03113G. The mouse 18S rRNA gene (cat-
alog #PPM57735E) was used as the housekeeping gene for normaliza-
tion. For each primer, the amount of template providing maximum
efficiency without inhibiting the PCR was determined during initial op-
timization experiments. For all experiments, dissociation curves were
generated to ensure that a single peak was obtained at the right melting
temperature without nonspecific amplicons. The fold change in gene
expression was determined by the Ct method using the threshold
cycle (Ct) value for the housekeeping gene and the respective target gene
of interest in each sample.
Western blotting. Brain tissue and microglial cell lysates were pre-
pared using modified RIPA buffer and were normalized for equal
amounts of protein using the Bradford protein assay kit. Equal
amounts of protein (12–25 g for cell lysates and 30–40 g for tissue
lysates) were loaded for each sample and separated on either 12% or
15% SDS-PAGE gels depending on the molecular weight of the target
protein. After separation, proteins were transferred to a nitrocellulose
membrane, and the nonspecific binding sites were blocked for 1 h
using a blocking buffer specifically formulated for fluorescent West-
ern blotting (Rockland Immunochemicals). Membranes were then
probed with the respective primary antibodies for 3 h at room tem-
perature or overnight at 4°C. After incubation, the membranes were
washed 7 times with PBS containing 0.05% Tween 20, and then sec-
ondary IR-680-conjugated anti-mouse (1:10,000, goat anti-mouse,
Invitrogen) and IR-800-conjugated anti-rabbit (1:10,000, goat anti-
rabbit, Rockland) were used for antibody detection with the Odyssey
IR imaging system (LiCor). Antibodies for -actin and tubulin were
used as loading controls.
Coimmunoprecipitation studies.We adopted an immunoprecipitation
protocol with slight modifications from Gao et al. (2011). Cell lysates
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were prepared in TNE buffer (10 mM Tris-HCl at pH 7.5, 1% Nonidet
P-40, 0.15 M NaCl, 1 mM EDTA, and 1:100 protease inhibitor mixture)
and centrifuged at 17,400 g for 40min at 4°C. The supernatant protein
concentration was measured and normalized between samples. Approx-
imately 20 l of the sample containing 50 g protein was used as input.
For immunoprecipitation analysis, 1 mg of protein in 400l TNE buffer
was used. Next, 10l (2g) of Fyn rabbit polyclonal antibody was added
to the lysates, and the samples were set on an orbital shaker overnight at
4°C. The next day, protein G Sepharose beads were spun down at
17,400 g for 5 min, and the ethanol supernatant was replaced with an
equal volume of the lysis buffer. The Protein G Sepharose slurry was
washed once, and 50 l was added to each sample. The samples were set
on an orbital shaker overnight at 4°C. Protein G beads were collected by
centrifugation at 2000  g for 5 min and were washed four times with
TNE buffer. The bound proteins were eluted by boiling in 2 protein-
loading dye for 5min. Immunoblots were performed on 12%SDS-PAGE
gels as described for Western blotting.
Nuclear and cytoplasmic fractionation. Nuclear and cytoplasmic frac-
tions were performed using the NE-PER kit (Thermo Scientific) as pre-
viously described (Jin et al., 2011a, 2014). Briefly, 5  106 cells were
treatedwith LPS or TNF for 15min. CER1 reagent (200l) was used for
each sample to extract the cytoplasmic fraction, and 50l ofNER reagent
was used to extract the nuclear fraction. Tubulin or -actin was used as a
cytosolic fractionmarker. Lamin Bwas used as a nuclear fractionmarker.
Fyn kinase assays. Cell pellets were washed with ice-cold PBS and re-
suspended in lysis buffer (25 mM HEPES at pH 7.5, 20 mM
-glycerophosphate, 0.1mM sodium orthovanadate, 0.1%Triton X-100,
0.3MNaCl, 1.5 mMMgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 10 mM
NaF, and 4 g/ml each of aprotinin and leupeptin) (Kaul et al., 2005).
Next, 50 g of crude protein was incubated with 150 mM Fyn kinase
substrate (Biomol), 100 mCi of [- 32P] ATP, Src-Mn-ATPmixture, and
Src reaction buffer (Millipore) for 10 min at 30°C with agitation. To
precipitate the Fyn kinase substrate peptide, 20l of 40% trichloroacetic
acid was added. Then 25 l of the mixture was spotted onto a P81 phos-
phocellulose square; and 5 min after spotting, the squares were washed
five times in 0.75% phosphoric acid in PBS with a final wash step in
acetone. The squares were transferred into a scintillation vial, and the
counts per minute were read in a liquid scintillation system after adding
5 ml of scintillation mixture to each vial.
PKC kinase assays. PKC IP kinase activity assays were performed as
described previously (Anantharam et al., 2002; Latchoumycandane et al.,
2011; Harischandra et al., 2014) with some modifications for microglial
cells. Briefly, primary microglial cells were collected after treatments,
washed in ice-cold PBS, and resuspended in a mild RIPA lysis buffer
containing protease and phosphatase inhibitor mixture (Pierce Biotech-
nology). The cells were placed on ice for 20 min to allow for complete
lysis and then centrifuged at 16,200  g for 45 min. The supernatant
protein concentration was determined using the Bradford protein assay
kit. Samples were normalized to a uniform total protein concentration of
2g/ml, and then 200g of total protein in a 250l reaction volumewas
immunoprecipitated overnight at 4°C using 5g of PKC antibody. The
next day, proteinA agarose beads (Sigma-Aldrich)were incubated for 1 h
at room temperature. The protein A-bound antibody complexes were
collected and washed 3 times in 2 kinase assay buffer (40 mM Tris, pH
7.4, 20mMMgCl2, 20MATP, and 2.5mMCaCl2), and then resuspended
in the same buffer. The kinase reaction was started by adding 40l of the
reaction buffer containing 0.4mg of histoneH1, 50g/ml phosphatidyl-
serine, 4 M dioleoylglycerol, and 10 Ci of [- 32P] ATP at 3000 Ci/mM
to the immunoprecipitated samples. The samples were then incubated
for 10 min at 30°C, and the kinase reaction was stopped by adding 2
SDS loading buffer and boiling for 5 min. Proteins were separated on a
15% SDS-PAGE gel, and the phosphorylated histone bands were imaged
using a Fujifilm FLA 5000 imager. Image analysis and band quantifica-
tion were performed using ImageJ.
Nitric oxide detection. Nitric oxide production by primary microglia
was measured indirectly by quantification of nitrite in the supernatant
using the Griess reagent (Sigma-Aldrich). Microglia were plated in poly-
D-lysine-coated 96-well plates at 1  105 cells/well. Cells were treated
with 100 ng/ml of LPS for 24 h; and after 100 l of supernatant was
collected from each well, an equal volume of the Griess reagent was
added. The samples were incubated on a plate shaker at room tempera-
ture for 15 min until a stable color was obtained. The absorbance at 540
nmwasmeasured using the Synergy 2multimodemicroplate reader, and
the nitrite concentration was determined from a sodium nitrite standard
curve.
Multiplex cytokine Luminex immunoassays. Primary microglia ob-
tained fromwild-type, PKC/, and Fyn/mice were seeded in poly-
D-lysine-coated 96-well plates at 1 105 cells/well. The cells were treated
for 24 h with 100–200 ng/ml LPS or 10 ng/ml TNF. After treatment, 50
l of supernatant from each well was collected and frozen at80°C. The
levels of cytokines and chemokines in the supernatants were determined
using the Luminex bead-based immunoassay platform (Vignali 2000)
and prevalidated multiplex kits (Milliplex mouse cytokine panel, Milli-
pore) according to the manufacturer’s instructions.
Diaminobenzidine immunostaining and grading of microglial morphol-
ogy. Diaminobenzidine (DAB) immunostaining was performed on stri-
atal and nigral sections as described previously (Ghosh et al., 2010).
Briefly, mice were perfused with 4% PFA, and brains were postfixed with
PFA for 48 h before storage in 30% sucrose. Fixed brains were embedded
in OCT compound (Tissue-Tek) and stored frozen at 80°C until the
frozen blocks were sliced into 30 m coronal sections using a cryostat.
Sections were probed with the primary antibodies overnight at 4°C and
then incubated with biotinylated anti-rabbit secondary antibody. The
sections were then treated with avidin peroxidase (Vectastain ABC Elite
kit). The DAB reagent was used for producing the brown colored stain.
Grading of microglial morphology was performed as described pre-
viously (Lastres-Becker et al., 2012). For microglial grading, images
were sharpened in ImageJ so the morphology could be more clearly
visualized. The cell counter function in the “Analyze” plugin was used
to count the number of Type A-D microglia in the ventral midbrain
sections.
Data analysis.Data analysis was performedusing Prism4.0 (GraphPad
Software). The data were initially analyzed using one-way ANOVA and
Bonferroni’s post-test to compare the means of treatment groups. Dif-
ferences of p 0.05 were considered statistically significant. Student’s t
test was used when comparing two groups.
Results
Fyn and PKC are differentially expressed in primary
astrocytes and microglia
Primary mouse microglia were prepared as described in our re-
cent publication using a magnetic separation method, which en-
ables us to obtain a high-yield pure fraction of microglia from
mixed glial cultures (Gordon et al., 2011). Iba-1 and GFAP im-
munocytochemistry confirmed that the microglial fraction ob-
tained after magnetic separation was devoid of astrocytes (Fig.
1A). Quantification ofHoechst colocalized Iba-1-positivemicro-
glia andGFAP-positive astrocytes using the ImageJ plugin JACoP
revealed a microglial population that was	97% pure after sepa-
ration (Fig. 1B,C). Immunoblotting analysis revealed that
microglia-enriched fractions expressed significantly more Fyn
(60 kDa) and PKC (76 kDa) than did astrocyte-enriched
(microglia-depleted) fractions (Fig. 1D,E). The differential ex-
pression of both Fyn and PKC in microglia compared with as-
trocytes prompted us to study the roles these proteinsmay play in
microglial proinflammatory signaling.
Fyn kinase is rapidly activated in microglial cells and in the
ventral midbrain following inflammogen stimulation
Our initial experiment to determine whether the non-receptor
tyrosine kinase Fyn plays a role in regulating neuroinflammatory
responses in PDwas performed in BV2microglial cells, which are
widely used in vitro models of neuroinflammation (Henn et al.,
2009; Gao et al., 2011; Kim et al., 2013b). We treated BV2 cells
with 1g/ml LPS for 10–60min andmeasured Fyn activity using
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an in vitro kinase assay (Saminathan et al., 2011). A kinase reac-
tionmixture containing 32P-ATP and a Fyn-specific peptide sub-
strate were added to whole-cell lysates. LPS stimulation of BV2
microglia rapidly induced Fyn activity as early as 10min after LPS
stimulation (Fig. 2A), and maximal activity was attained 30 min
after LPS stimulation. In addition to the Fyn kinase activity assay,
we also determined the phosphorylation status of the Y416 resi-
due in its activation loop domain by using the phospho Y416 Src
family kinase (p-Y416 SFK) antibody, which recognizes activated
Src family kinases. This antibody has been used extensively to
demonstrate Fyn kinase activation (Wake et al., 2011; Kouadir et
al., 2012; Larson et al., 2012; Um et al., 2012). Our immunoblot-
ting analysis of LPS-treated BV2 lysates using the p-Y416 SFK
antibody revealed LPS-induced SFK activation (Fig. 2B). To fur-
ther confirm inflammogen-induced Fyn activation in BV2 mi-
croglia, we transiently transfected BV2 cells with FLAG-tagged
WT-Fyn and Y417A-Fyn (activation loop mutant) constructs.
We then performed immunoprecipitation studies in LPS-
treated transfected BV2 cells. We pulled down Fyn from
FLAG-tagged WT-Fyn and Y417A-Fyn transfected, LPS-
treated BV2 cells and immunoblotted for p-Y416 SFK levels. A
strong p-Y416 SFK signal was detected in the LPS-treatedWT-Fyn-
FLAG-transfected cells, but not in the LPS-treated Y417A-Fyn-
transfected cells (Fig. 2C,D).
Next, we extended our studies to primary microglia derived
from both wild-type and Fyn-deficient (Fyn/) mice. These
were treated with 200 ng/ml LPS for 0–30 min. In line with the
analyses of BV2 cells, stimulation of the primary microglia from
Fyn/mice rapidly increased the levels of p-Y416 SFK (Fig. 2E).
Interestingly, p-Y416 SFK was not detected in LPS-treated
Fyn/microglia, suggesting that LPS preferentially induces Fyn
phosphorylation in microglia over other Src family kinases.
Treatment of wild-type and Fyn-deficient microglia with TNF
also yielded similar results. Both 10 ng/ml and 30 ng/ml TNF
treatments induced similar levels of p-Y416 SFK inwild-type, but
not in Fyn-deficient microglia (Fig. 2F). Pretreatment of wild-
typemicroglia with either the Toll-like receptor (TLR) antagonist
IAXO-101 or the TNF signaling antagonist etanercept signifi-
cantly attenuated both LPS- and TNF-mediated Fyn activation,
respectively (Fig. 2G). We also examined subcellular localization
of activated Fyn following LPS stimulation. The Iba-1/p-Y416
SFK double-immunocytochemical analysis showed that LPS
treatment dramatically increased p-Y416 Fyn levels in WT pri-
mary microglia (Fig. 2H). Active Fyn seems to be preferentially
expressed at the periphery of themicroglia, possibly allowing it to
become activated quickly in response to a proinflammatory stim-
ulus. Additionally, activated Fyn was also found in the nucleus of
LPS-treated primary microglia. Next, we wanted to confirm that
Figure 1. Fyn and PKC are differentially expressed in primary astrocytes and microglia. A, Representative image from immunocytochemical analysis for the microglial marker Iba-1
and the astrocytic marker GFAP on both the magnetically purified and pour-off fractions of cells obtained after separation revealed almost no astrocytic contamination in the samples.
Scale bar, 200 m. B, The colocalization image of Hoechst (nuclear stain) and Iba-1 images in 6 random image fields were obtained using the ImageJ plugin JACoP. C, The number of
Hoechst-positive and colocalization-positive cells were counted using ImageJ. The magnetically purified samples were97% positive for microglial cells. D, E, Western blot analyses of
the magnetically separated cells revealed that the microglial fraction expressed higher amounts of the non-receptor Src kinase Fyn and the serine threonine kinase PKC than did the
astrocyte-rich pour-off fraction. *p 0.05. **p 0.01.
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LPS treatment would activate Fyn in the SN of mice. Knowing
that a single intraperitoneal LPS injection elicits microglial cell
activation in the SN (Qin et al., 2007), we challenged Fyn/ and
Fyn/ mice with 5 mg/kg LPS or sterile PBS vehicle intraperi-
toneally for 3 h. Immunoblot analysis of ventral midbrain lysates
revealed that LPS significantly increased p-Y416 SFK levels in
wild-type compared with saline control, whereas LPS failed to
increase p-Y416 SFK levels in the Fyn/ ventralmidbrain lysates
(Fig. 2I). These studies indicate that stimulating microglia with
inflammatory stimuli rapidly activates Fyn kinase in both cell
culture and animal models of neuroinflammation.
Fyn contributes to LPS- and TNF-induced tyrosine
phosphorylation and activation of PKC in primary
microglia
It has been shown that Src family kinases, including Fyn,
phosphorylate PKC at residue Y311 in platelets and in im-
mortalized dopaminergic neuronal cells (Steinberg, 2004;
Saminathan et al., 2011). Therefore, we investigated whether
Fyn-PKC signaling regulates microglial proinflammatory re-
sponses using primary microglia cultures from wild-type,
Fyn/, and PKC/ mice. Stimulation with LPS induced a
rapid and time-dependent increase in p-Y311 PKC in wild-
type microglia. In contrast, LPS failed to increase Y311 phos-
phorylation of PKC in the Fyn/ microglia (Fig. 3A,B).
Similarly, TNF stimulation of microglia also increased PKC
Y311 phosphorylation in wild-type, but not in Fyn-deficient
primary microglia (Fig. 3C,D). As expected, immunoblot
analysis did not detect any LPS-induced phosphorylation of
Y311 PKC in PKC/ microglia (Fig. 3A). To confirm fur-
ther that Fyn mediates the activation of PKC in activated
microglia, we measured PKC kinase activity in wild-type and
Fyn/ microglia. An in vitro PKC kinase assay showed that
LPS rapidly increased PKC kinase activity in wild-type mi-
croglia; however, LPS-induced PKC kinase activity was sig-
nificantly less in Fyn/ microglia (Fig. 3E). To further
confirm the Fyn-PKC interaction, we performed coimmuno-
precipitation studies in BV2 cells transfected with the
WT-Fyn-FLAG construct. As shown in Figure 3F,G, coimmuno-
precipitation analysis ofWT-Fyn-FLAG-transfected lysates revealed
that Fyn and PKC interact during LPS stimulation. Together with
the PKC kinase activity results, these data reveal that Fyn kinase
mediates LPS- and TNF-induced activation of PKC in primary
microglia.
The Fyn-PKC signaling axis mediates MAP kinase activation
in microglial cells
We next examined whether the Fyn-PKC signaling axis plays
a role in mediating activation of the MAP kinase pathway, a
key hallmark of neuroinflammatory signaling in microglia.
MAP kinases are important regulators of proinflammatory
cytokine synthesis in microglial cells (Koistinaho and Koisti-
naho, 2002; Tansey and Goldberg, 2010). For this purpose, we
treated wild-type, Fyn/, and PKC/ microglia with LPS
for 15, 30, and 45 min each and determined MAPK activation.
The LPS treatment significantly increased the phosphoryla-
Figure 2. Fyn kinase is rapidly activated in microglial cells and in the ventral midbrain following inflammogen stimulation. A, Fyn kinase assay shows that Fyn activity was highly
induced in BV2 microglia treated with 1g/ml LPS for 10, 15, and 30 min. *p 0.05. **p 0.01. B, Immunoblots showing a concomitant rise in p-Y416 SFK levels in BV2 cell lysates
after LPS treatment. C, D, Immunoprecipitation studies revealed that WT Fyn, but not activation loop tyrosine-mutant Fyn (Y417A Fyn), when overexpressed in BV2 microglia, was
activated following LPS stimulation. E, F, Treatment of (E) primary microglia with LPS and TNF (F ) for 15 and 30 min increased p-Y416 SFK levels in primary microglia obtained from
Fyn/, but not Fyn/ mice, identifying Fyn as the primary Src family kinase that was activated by inflammogen stimulation. G, Pretreatment of primary microglia with the
TLR-signaling antagonist IAXO-101 or the TNF receptor decoy etanercept abolished Fyn activation by LPS or TNF stimulation (p44/42 phosphorylation used as marker for early
microglial activation). H, Immunocytochemistry of LPS-treated WT primary microglia showing that activated Fyn expression greatly increased and was localized preferentially to the
membrane periphery of the microglial cell. Scale bar, 20 m. I, Immunoblots of ventral midbrain lysates showed that peripheral administration of the inflammogen LPS (5 mg/kg)
increased p-Y416 SFK levels in Fyn/, but not in Fyn/ ventral midbrain tissues.
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Figure 4. The Fyn-PKC signaling axis mediates MAP kinase activation in microglial cells. A, B, Immunoblot analysis demonstrated diminished LPS-induced p38 and p44/42 (ERK) phosphory-
lation in Fyn/ and PKC/microglia. *p 0.05. ***p 0.001. C, D, Diminished TNF-induced p38 and p44/42 (ERK) phosphorylation in Fyn/ and PKC/microglia. *p 0.05.
Figure 3. Fyn contributes to LPS- and TNF-induced tyrosine phosphorylation and activation of PKC in primarymicroglia.Western blot analysis revealed that stimulation ofmicrogliawith LPS
(A,B) and TNF (C,D) induced a time-dependent increase in p-Y311 PKC levels in wild-type but not Fyn/microglia. *p 0.05. **p 0.01. E, LPS-induced PKC kinase activity was reduced
in Fyn/microglial lysates in contrast to wild-type lysates, as measured by PKC kinase assay. F, G, Coimmunoprecipitation studies showed that LPS stimulation elicited a physical interaction
between Fyn and PKC in WT Fyn-transfected BV2 microglial cells.
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tion of p38 and p44/42 (ERK) kinases in wild-type microglia
(Fig. 4A,B), with LPS-induced phosphorylation peaking at 15
min and decreasing thereafter. In contrast, LPS-induced phos-
phorylation of p38 and p44/42 was significantly reduced in
Fyn/ and PKC/ primary microglia. Similar results were
obtained with TNF treatment of wild-type, Fyn/, and
PKC/ microglia (Fig. 4C,D). These results suggest that
Fyn-PKC signaling is an important upstream regulator of
MAP kinases in microglia during both LPS and TNF
stimulation.
Fyn contributes to inflammogen-mediated NFB pathway
activation in microglial cells
Proinflammatory signaling mediated by both LPS and TNF
converges at the NFB pathway. Activation of NFB signaling
during the proinflammatory process is characterized by the
phosphorylation and subsequent degradation of the inhibi-
tory protein IB, after which the NFB p65-p50 heterodimer
enters the nucleus, leading to the transcription of various pro-
inflammatory genes (Hayden and Ghosh, 2004). To elucidate
whether Fynmediates the nuclear translocation and activation
of NFB signaling in activated microglia, primary microglia
obtained from wild-type and Fyn/ microglia were treated
with LPS for 15–45 min. Whole-cell lysates were prepared and
probed for IB. LPS treatment induced a greater degradation
of IB in wild-type microglia than in Fyn/microglia at the
15 min time point, followed by the resynthesis of IB 30 and
45 min after stimulation in the WT cells. Resynthesis of IB
in Fyn/ microglia was almost completely abrogated, indi-
cating diminished NFB activation (Fig. 5A,B). Next, we in-
vestigated the role of Fyn in the nuclear translocation of the
p65 component of the NFB complex in response to LPS and
TNF treatments. Nuclear and cytoplasmic fractions were pre-
pared fromWTandFyn/microglia treatedwithLPSorTNF for
Figure 5. Fyn contributes to inflammogen-mediated NFB pathway activation in microglial cells. A, B, Immunoblot analyses of whole-cell lysates of wild-type and Fyn/microglia treated
with LPS for 15–45min revealed reduced IB degradation in Fyn/microglia at 15min, and attenuated IB resynthesis at 30 and 45min. *p 0.05. **p 0.01. C,D, Cytosolic and nuclear
fractionation of LPS- and TNF-treatedwild-type and Fyn/microglia revealed diminished nuclear translocation of the p65 subunit of the NFB complex in the Fyn/microglia. **p 0.01.
***p 0.001. E, Immunocytochemistry also showed reduced nuclear p65 in LPS-treated Fyn/microglia. Scale bar, 50m.
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15 min before being assessed for p65 content. Immunoblotting
revealed lesser nuclear translocation of p65 in LPS- and TNF-
treated Fyn/ microglia than in wild-type microglia (Fig.
5C,D). These results were further supported by Iba-1/p65 double-
immunocytochemistry showing strong LPS-induced nuclear trans-
location of p65 in wild-type, but not in the Fyn/microglia (Fig.
5E). Together, these results clearly suggest that Fyn kinase regulates
NFB activation inmicroglial cells.
LPS- or TNF-induced proinflammatory cytokine
production is suppressed in Fyn/PKC-deficient microglia
Next, we determined whether Fyn-PKC signaling axis
regulates microglia-mediated proinflammatory mediator pro-
duction. After treating wild-type, PKC/, and Fyn/ mi-
croglial cultures with LPS or TNF, we used multiplexed
immunoassays to quantify inflammogen-induced cytokine se-
cretion. We observed significant production of the cytokines
Figure 6. LPS- or TNF-induced proinflammatory cytokine production is suppressed in Fyn/PKC-deficient microglia. A, Luminex analyses of supernatants from LPS-treated
wild-type, PKC/, and Fyn/ microglia revealed reduced secretion of the proinflammatory cytokines IL-6, IL-12, and TNF. **p 0.01. ***p 0.001. B, Wild-type primary
microglia were transfected with nontargeting and Fyn-specific siRNA for 72 h. Knockdown of Fyn was evaluated byWestern blot. C, Fyn-depletedmicroglia demonstrated diminished IL-6
and TNF secretion in response to LPS stimulation. **p 0.01. ***p 0.001. D, TNF stimulation of Fyn/ microglia reduced IL-6 and TNF production in contrast to wild-type
microglia. **p  0.01. ***p  0.001. E, Immunoblots showing reduced TNF levels in Fyn-deficient microglia after TNF stimulation in contrast to wild-type microglia. F, G,
Overexpressing the FLAG-tagged activation loop tyrosinemutant of Fyn in BV2microglia attenuated IL-6 and IL-12 production when the cells were treated with LPS, as shown by Luminex
cytokine analysis. *p 0.05. **p 0.01. ***p 0.001.
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IL-6, IL-12p70, and TNF from wild-type microglia treated
with LPS (Fig. 6A). However, the production of these cyto-
kines was significantly dampened in Fyn- and PKC-deficient
microglia, providing evidence for the hypothesis that attenu-
ated proinflammatory signaling in Fyn/ and PKC/ mi-
croglia suppresses proinflammatory mediator production.
When we knocked down Fyn expression in wild-type primary
microglia by Fyn-specific siRNA (Fig. 6B), diminished
amounts of the proinflammatory cytokines IL-6 and TNF
were produced in response to LPS treatment (Fig. 6C). Next,
treatment of wild-type and Fyn/ microglia with TNF
yielded similar results, with the Fyn/ microglia showing
reduced IL-6 and TNF production (Fig. 6D). Western blot
analysis also demonstrated that Fyn-deficient microglia pro-
duced less TNF relative to wild-type microglia (Fig. 6E). To
further confirm the role of Fyn in proinflammatory cytokine
production, we expressed Fyn wild-type (WT-Fyn-FLAG) or
activation loop mutant (kinase-deficient Fyn kinase, Y417A
Figure 7. Fyn plays a role in LPS-induced iNOS expression, nitrite production, and neuroinflammatory marker expression. A, Griess nitrite measurement assay demonstrated that LPS-induced
nitrite productionwas reduced in Fyn/microglia. *p 0.05. ***p 0.001.B–D, Diminished iNOS expression in LPS-treated Fyn/microglia. **p 0.01. Scale bar, 100m. E, F, Reduced
gp91 phox and Iba-1 expression in LPS-treated Fyn/ and PKC/microglia, as shown by immunoblotting analysis. *p 0.05. **p 0.01.
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Figure 8. Fyn/ andPKC/mice are resistant to LPS- andMPTP-inducedneuroinflammatory responses.A,Wild-type, PKC/, and Fyn/micewere injected intraperitoneallywith 5mg/kg
LPSfor3h.Striatal cytokinemRNAlevels,assessedbyqRT-PCR, showedsignificantly reduced inductionofpro-IL-1andTNFmRNAlevels inPKC/andFyn/mice incontrast towild-typemice.*p
0.05.**p0.01.***p0.001.B, The transitional stagesofmicroglial activation, fromramified (inactivated,TypeA) toamoeboid (activated,TypesB-D), are shownby representative images.C,D, Iba-1-DAB
immunohistochemistry inMPTP-injectedFyn/ andwild-typeventralmidbrain sectionsdemonstratednigralmicrogliosis, assessedbyquantificationofmicroglialmorphology, in thewild-type, butnot the
Fyn/ sections.Scalebar,75m.*p0.05.**p0.01.ns,Notsignificant.E,F, Fyn/miceshoweddiminished inductionof theproinflammatorymarkergp91phox inventralmidbrain lysates following
the acuteMPTP regimen. *p 0.05.
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Fyn-FLAG) in BV2 microglial cells (Fig. 6F ). Following the
transfection, BV2 cells transfected WT-Fyn-FLAG, Y417A
Fyn-FLAG, or empty vector constructs were treated with 1
g/ml LPS for 24 h. Luminex immunoassay of cell superna-
tants revealed that overexpressing wild-type Fyn augmented
proinflammatory cytokine release, whereas overexpressing the
activation loop Y417A Fyn mutant suppressed the production
of IL-6 and IL-12 (Fig. 6F,G).
Fyn/PKC regulates the induction of neuroinflammatory
markers iNOS and gp91phox in microglia during LPS
stimulation
We further assessed whether Fyn alters the induction of iNOS
and gp91phox, which are key proinflammatory responses of mi-
croglial activation following LPS treatment. Treatment with LPS
induced a stronger nitrite response from wild-type microglia
than from Fyn/ microglia (Fig. 7A). This was further con-
firmed by immunostaining and immunoblotting for iNOS, the
enzyme that mediates nitrite production. There was a greater
induction of iNOS in Fyn wild-type microglia relative to Fyn/
microglia (Fig. 7B–D). We also determined the expression of
other key neuroinflammatory markers, including gp91phox and
Iba-1, in response to LPS stimulation.We, aswell as other groups,
have previously shown increased expression of the NADPH oxi-
dase component gp91phox and Iba-1 following LPS stimulation of
primary microglia (Gao et al., 2011; Gordon et al., 2011). West-
ern blot analysis revealed that LPS increased expression of both
gp91phox and Iba-1 in wild-type, but not in Fyn/ or PKC/
microglia (Fig. 7E,F). Collectively, these data indicate that Fyn-
PKC signaling plays amajor proinflammatory role inmicroglial
cells.
Fyn/ and PKC/mice are resistant to LPS- andMPTP-
induced neuroinflammatory responses
To extend our findings from isolated primarymicroglia to in vivo
animal models of neuroinflammation, we first used the LPS
model, which has previously been used to evoke neuroinflamma-
tory responses in vivo (Choi et al., 2007; Qin et al., 2007). Wild-
type (PKC/ and Fyn/), PKC/, and Fyn/mice were
injectedwith 5mg/kg LPS or PBS andwere killed 3 h later. Striatal
mRNA contents of the proinflammatory cytokines pro-IL-1
and TNF were determined by qRT-PCR. The levels of cytokine
inductionwere almost identical in bothwild-type groups, andwe
thus pooled the results. Systemic LPS administration strongly
increased the levels of pro-IL-1 and TNF transcripts in wild-
type striata, but not in Fyn/ and PKC/ striata (Fig. 8A). To
further establish the role of Fyn relevant to PD-associated neuro-
inflammation, we used the well-known Parkinsonian toxicant
MPTP. We subjected wild-type and Fyn/ mice to an acute
MPTP regimen (4  18 mg/kg, 2 h apart) and collected their
Figure 9. Fyn/mice are protected against 6-OHDA-induced nigrostriatal dopaminergic neuronal deficits and microgliosis. A, TH-DAB immunohistochemistry in 6-OHDA-injected Fyn/
and wild-type mouse striatal sections. Scale bar, 1000 m. B, Schematic diagram of a coronal section through the mouse striatum at the level of the injection. C, Significant preservation of
6-OHDA-induceddegenerationof dopaminergic terminals is seen in the Fyn/mice in contrast towild-typemice. **p0.01. ***p0.001.D, Immunofluorescence stainingof 6-OHDA-injected
Fyn/ andwild-type ventral midbrain sections reveals diminishedmicrogliosis and concomitant nigral neuroprotection in Fyn/mice after 6-OHDA administration, in contrast to themassive
microgliosis and nigral dopaminergic neuronal death observed in the wild-type mice. Scale bar, 200m.
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brains for immunohistochemical analysis 24 h after the final MPTP
injection. This acute MPTP model has been widely adopted for
studying the neuroinflammatory response in the nigrostriatal path-
way becausemaximalmicroglial activation occurs 24–48 h after the
MPTP challenge (Wu et al., 2002, 2003; Sriram et al., 2006; Hirsch
andHunot, 2009). Following theMPTPchallenge, successive 30m
ventral midbrain sections from Fyn/ and Fyn/ mice were
stained for the microglial marker Iba-1, and then microglial mor-
phology was quantified using a recently well-established morpho-
metric rating scale as discussed by others (Lastres-Becker et al.,
2012). Representations of Type A-D microglial phenotype are pro-
vided in Figure 8B. Treating Fyn/ mice with the acute MPTP
regimen increased Iba-1 expression and discernibly shifted micro-
glial morphology from its typical ramified state to its more amoe-
boid, activated morphology. After MPTP administration,
significantly fewer Type A and more Type B and C microglia were
observed in the Fyn/ SN, but this shift inmicroglial morphology
was not apparent in the Fyn/ mice (Fig. 8C,D). We also deter-
mined the inductionof theNADPHoxidase componentgp91phox in
MPTP animal model of neuroinflammation. Immunoblotting
analysis revealed that MPTP increased expression of gp91phox
in WT but not in Fyn/ ventral midbrain tissues (Fig. 8E,F ).
Overall, these results confirm that our in vitro data translate
well to animal models of neuroinflammation.
Fyn/ and PKC/mice are protected against 6-OHDA-
induced nigrostriatal dopaminergic neuronal deficits and
microgliosis
The 6-OHDAmouse model has recently been shown to elicit a
neuroinflammatory response and neurodegeneration in the
Figure10. PKC/mice are resistant to 6-OHDA-inducednigrostriatal dopaminergic neuronal deficits andmicrogliosis.A, TH-DAB immunohistochemistry in 6-OHDA-injected PKC/ and
wild-typemouse striatal sections. Scale bar, 1000m.B, Schematic diagramof a coronal section through themouse striatumat the level of the injection.C, Significant preservation of dopaminergic
terminals is seen in the 6-OHDA-treated PKC/mice in contrast to wild-typemice. *p 0.05. **p 0.01. ***p 0.001.D, Immunofluorescence staining of 6-OHDA-injected PKC/ and
wild-type ventral midbrain sections reveals reduced nigral TH degeneration andmicrogliosis in PKC/mice after 6-OHDA administration, in contrast to the wild-typemice. Scale bar, 200m.
E, High-magnification image of 6-OHDA-injected PKC/ and wild-type ventral midbrain sections. Scale bar, 50m.
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nigrostriatal dopaminergic system (Stott and Barker, 2014).
While studying the role of Fyn in dopamine D1 receptor
agonist-induced redistribution of NMDA receptor subunits, it
was serendipitously discovered that Fyn/ mice were re-
markably resistant to 6-OHDA-induced behavioral deficits
and striatal TH loss (Dunah et al., 2004). Fyn/ and Fyn/
mice, injected unilaterally with 6-OHDA (Fig. 9B), were killed
9 d after treatment because mice at this treatment stage concur-
rently exhibit fewer striatal dopaminergic terminals, significantly
fewer TH-positive cells in the SN, andmicrogliosis within the SN
(Stott and Barker, 2014). Fyn/ mice were more resistant to
6-OHDA-induced striatal nerve terminal degeneration relative
to Fyn/ mice (Fig. 9A,C). We also show in our studies that
6-OHDA induced massive gliosis coupled with dopaminergic
neuronal loss (Fig. 9D). However, Fyn/ mice show both
greater survival of nigral dopaminergic neurons and a dimin-
ished neuroinflammatory microglial response.
In the next set of in vivo experiments, we checked whether
PKC/ mice were also resistant to 6-OHDA-induced nigral
microgliosis and dopaminergic neuronal loss. PKC/ and
PKC/mice were injected unilaterally with 6-OHDA for 9 d,
and DAB-TH immunostaining was performed on striatal sec-
tions as described above (Fig. 10B). Similar to Fyn/ mice,
PKC/ mice showed reduced striatal TH loss following
6-OHDA treatment (Fig. 10A,C). We also assessed nigral micro-
gliosis by double-staining ventral midbrain sections for TH and
Figure 11. Diminished 6-OHDA-induced glial-neuronal contact (gliapse) formation in the Fyn/ SN. A, C, Confocal Z-stack maximum projection image analysis of ventral midbrain sections
reveals a strongly increased number of microglial-neuronal contacts and appositions upon 6-OHDA treatment of Fyn/ but not Fyn/mice. Scale bar, 12m. B, D, Confocal Z-stack images
were rotated and optically sectioned along the Z-plane using Imaris software, allowing easy visualization of gliapse formation. Scale bar, 10m. E, Diagrams of Process-Body (Pr-B) and Body-Body
(B-B)gliapses formedbetweendopaminergic neurons andmicroglia.F, Fyn ventralmidbrain sections revealed significantly fewergliapses formedperdopaminergic neuron in theSN. ***p0.001.
ns, Not significant.
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Iba-1. As shown in Figure 10D, E, PKC/ mice showed less
TH-positive neuronal staining in the SN along with significantly
more microgliosis on the ipsilateral side than on the contralateral
side; however, the PKC/ mice showed a marked resistance to
6-OHDA-induced nigral TH loss as well as microgliosis. Thus, re-
sults from both Fyn and PKC knock-outmodels of 6-OHDAneu-
rotoxicity confirm the role of the Fyn-PKC signaling axis in a
neuroinflammatory response in the nigrostriatal dopaminergic
system.
Diminished 6-OHDA-induced glial neuronal contact
formation in the Fyn/ SN
Recently, it was demonstrated that treatingmice withMPTP rap-
idly increased the number of microglial-neuronal appositions,
termed gliapses (Barcia et al., 2012). These contacts preceded
neuronal phagocytosis by the microglia. Similar appositions be-
tween microglia and dopaminergic neurons were demonstrated
in the 6-OHDA model, with evidence suggesting that microglial
cells actually phagocytized neurons (Virgone-Carlotta et al.,
2013), which has been postulated to occur if the neurons are
dysfunctional. Our confocal high-magnification Z-stack image
analysis (Imaris software) revealed a sharply increased number of
microglial-neuronal contacts formed in the Fyn/ SN after
6-OHDA treatment as indicated in Fig. 11A, B, F (arrowhead).
The 3D reconstructions of the respective stacks demonstrating
contacts between dopaminergic neurons and microglia are
shown adjacent to the original images (Fig. 11B). The number of
gliapses per SN dopaminergic neuron was dramatically reduced
in the 6-OHDA-injected Fyn/ mice (Fig. 11C,D,F). Typical
contacts formed betweenmicroglial processes and dopaminergic
neuronal cell bodies (termed Process-Body, or Pr-B contacts),
and those formed between themicroglial cell body and the dopa-
minergic neuronal cell body (Body-Body, or B-B contacts), are
shown in Figure 11E. Image analysis involving optical slices
through the Z-plane allowed us to both easily count gliapses and
visualize actual engulfment events. Representative (Fig. 11B,D)
gliapses between a dopaminergic neuron and a microglial cell in
the SN of 6-OHDA-injected Fyn/ and Fyn/ mice reveal a
conspicuous reduction in the number of gliapses per neuron.
Collectively, our confocal imaging results demonstrate that Fyn
plays a key role in activation ofmicroglial morphological changes
in vivo during inflammatory insults in nigrostriatal system.
Prolonged inflammogen stimulation causes Fyn induction
uponmicroglial activation
Thus far, our results demonstrated that short-term treatment of
microglial cells with LPS and TNF brings about an increase in
Fyn activity, but not its expression. Strikingly, we discovered that
prolonged treatment (12–24 h) of microglia with LPS or TNF
actually resulted in increased Fyn expression, evidenced byWest-
ern blot and immunocytochemistry (Fig. 12A–C). To confirm
whether this is really due to induction of Fyn protein or increased
protein stability, we performed qRT-PCR for FynmRNA expres-
sion in control and LPS-treated microglial cells. The result
showed that treatment of microglia with LPS for 12 h brought
about an increase in Fyn transcript levels (Fig. 12D). We also
evaluated the effects of prolonged LPS treatment on Fyn pro-
moter activity. For this, we transiently transfected primary mi-
croglia with a dual-luciferase Fyn reporter construct containing
the 3.1 kb Fyn promoter fragment. LPS treatment significantly
Figure 12. Prolonged inflammogen stimulation induces Fyn uponmicroglial activation. A, B, Stimulation of primary microglia with LPS for 12 h and TNF for 24 h increased Fyn expression, as
evidenced byWestern blotting. *p 0.05. C, Immunohistochemistry analysis of Fyn expression. Scale bar, 20m.D, qRT-PCR analysis of FynmRNA levels in LPS-stimulated primarymicroglia and
BV2 microglia revealed induction of Fyn at the message level. *p 0.05. **p 0.01. E, Induction of Fyn promoter activity in primary microglia following LPS activation of wild-type primary
microglia. *p 0.05. F, Increased striatal Fyn mRNA levels were seen in the Fyn/mice injected intraperitoneally with LPS (5 mg/kg) for 12 h, as assessed by qRT-PCR. **p 0.01.
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increased Fyn promoter activity (Fig. 12E), indicating strongly
that Fyn is transcriptionally induced in microglial cells after pro-
longed inflammogen administration. To further examine
whether LPS upregulates Fyn mRNA expression, we injected
wild-type mice with a single dose of LPS (5 mg/kg, i.p.) and
evaluated the Fyn mRNA expression by qRT-PCR analysis. As
shown in Figure 12F, administration of LPS also induced Fyn
transcript levels in the striatum. Together, these data suggest that
prolonged LPS exposure induces Fyn gene upregulation in mi-
croglia, indicating that Fyn may have a sustained role in chronic
neuroinflammatory processes.
Discussion
Evidence from experimentalmodels and human PDpostmortem
studies strongly implicates themicroglia-mediated inflammatory
response as amajor driver in the progression of PD; however, the
key upstream cell signaling mechanisms that govern the neuro-
inflammatory processes have yet to be elucidated. Our results
obtained fromboth cell culture and animalmodels provide novel
insight into the role of the Fyn-PKC signaling cascade in regu-
lating microglia-mediated neuroinflammation as related to PD
pathogenesis. We have demonstrated dual regulation of proneu-
roinflammatory responses in microglia involving post-
translational tyrosine phosphorylation of Fyn at its activation
loop during the early stages of an inflammatory insult as well as
transcriptional upregulation of Fyn upon prolonged exposure to
proinflammatory stimuli. We have also shown that Fyn serves as
a major upstream signaling molecule that works in concert with
PKC to influence MAP kinase downstream and the NFB pro-
inflammatory cascade. Collectively, our study provides novel and
significant insight into the proinflammatory function of Fyn-
PKC signaling in PD models; and to the best of our knowledge,
we are the first to discern this key signaling cascade that is relevant
to microglia-mediated neuroinflammation in the nigrostriatal
dopaminergic system.
We demonstrate that both the tyrosine kinase Fyn and the
serine/threonine kinase PKC are differentially expressed in mi-
croglia and astrocytes (Fig. 1). No prior comparative data are
available on Fyn and PKC expression in primary microglia. Al-
though the roles of Src family kinases in TLR signaling are being
identified, most studies have used peripheral immune and non-
immune cells to determine Src kinase signaling. For example,
multiple Src family kinases were activated by LPS in human lung
microvascular endothelial cells (Gong et al., 2008). The activation
of Src kinases mediated by TLR agonists depends on CD14,
TLR2, and TLR4 (Reed-Geaghan et al., 2009), and Fyn has been
shown to be associated with TLR2 in TLR2-overexpressing
HEK293 cells (Finberg et al., 2012). Peritonealmacrophages have
often been used as putative substitutes for brain microglia; Fyn
contributes to CD36-mediated signaling responses upon A1–42
stimulation of macrophages (Moore et al., 2002). Of note, the
authors reported unaltered LPS-induced MAP kinase activation
in Fyn/ peritoneal macrophages compared with WT macro-
Figure 13. Proposed scheme of Fyn-mediated neuroinflammatory signaling pathway in microglia. LPS and TNF bind to their receptors, TLR4 and TNFR1, respectively, leading to early Fyn
activation. Fyn then phosphorylates and activates PKC, which leads to the downstream activation of the MAP kinase and NFB pathways. The p65 component of the NFB complex enters the
nucleus and binds to the promoter of various proinflammatory cytokine genes. Fyn is also upregulated to sustain the heightened inflammatory response during prolonged stimulation ofmicroglia,
possibly contributing to progressive neurodegeneration in PD.
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phages. These apparent discrepancies may be attributed to the
inherent differences between the microglial and macrophage
gene expression profiles (Hickman et al., 2013). Many studies
have used the p-Y416 Src family kinase antibody as a direct indi-
cator of Fyn activation, without using immunoprecipitation or
Fyn/ primary microglia as confirmatory tools to establish Fyn
activation. In the present study, we demonstrate that Fyn is rap-
idly activated in primarymicroglia within 15–30min of exposure
to inflammogens (Fig. 2A–F). Immunoprecipitation studies and
experiments with Fyn/ microglia clearly confirmed that Fyn
kinase is specifically activated during LPS and TNF stimulation.
LPS and TNF activate microglia/macrophages via TLR4 and
TNF receptor 1 (TNFR1) signaling, respectively (Olson and
Miller, 2004; Parameswaran and Patial, 2010). Importantly, our
study reveals that Fyn is a common signaling conduit in both
TLR- and TNFR1-mediated signaling because the TLR antago-
nist IAXO-101 and the TNF signaling antagonist etanercept
attenuated Fyn activation (Fig. 2G). Immunocytochemistry anal-
ysis revealed that activated Fyn primarily localized to the micro-
glial cell membrane. Although the functional relevance of this
localization is not presently known, it is possible that movement
of activated Fyn to the microglial membrane may regulate cell
migration and cytokine release. Our results with the LPS mouse
model provide in vivo evidence for rapid Fyn activation in the
ventral midbrain region during inflammatory insults (Fig. 2I).
Our group has previously shown that PKC kinase proteolytic
activation promotes oxidative stress-induced proapoptotic sig-
naling pathways in dopaminergic neuronal cells (Kaul et al.,
2003; Zhang et al., 2007; Jin et al., 2011a, b). Recently, it was
demonstrated that PKC is proteolytically cleaved by caspase-3
in LPS-treated BV2 cells (Burguillos et al., 2011). In the present
study, we demonstrate that activated Fyn associates with PKC to
phosphorylate the Y311 site, resulting in increased PKC kinase
activity (Fig. 3). To the best of our knowledge, we are the first
group to show the assembly of the Fyn-PKC signaling complex
in microglial cells during proinflammatory conditions.
MAP kinase activation is necessary for cytokine production
in various immune cell types, including microglia (El Benna et
al., 1996; Koistinaho and Koistinaho, 2002). We demonstrate
that Fyn-PKC signaling contributes to MAP kinase phos-
phorylation during microglial activation. Both LPS and TNF
stimulations rapidly activated the p38 and ERK MAP kinases
in WT, but to a significantly lesser extent in the Fyn/ and
PKC/microglia (Fig. 4), indicating that Fyn-PKC signal-
ing lies upstream ofMAP kinase inmicroglia. Given that p38 is
a prominent MAP kinase associated with the inflammatory
cascade, our results suggest that Fyn and PKC are key up-
stream regulators of the proinflammatory function of this ki-
nase. The downstream events of MAP kinase activation
include NFB signaling, which plays a cardinal role in eliciting
proinflammatory responses in microglia. Selective inhibition
of NFB signaling has also proved beneficial in vitro as well as
in an experimental mouse model of PD (Ghosh et al., 2007).
We show here that IB degradation and p65-NFB nuclear
translocation were diminished in Fyn/ microglia stimu-
lated with LPS or TNF (Fig. 5), lending credence to the hy-
pothesis that upstream Fyn signaling contributes to NFB
pathway activation in microglia. To our knowledge, the role of
Fyn signaling in NFB-mediated proinflammatory signaling
in microglia has never been explored. Fyn has been shown to
contribute to anaphylaxis inducer DNP36-HSA mediated
NFB activation in mast cells (Gomez et al., 2005). More re-
cently, Fyn was shown to mediate the nuclear translocation of
p65-NFB downstream of NKG2D and CD137 activation in
natural killer cells, using a signaling mechanism dependent on
adhesion- and degranulation-promoting adaptor protein
(ADAP) (Rajasekaran et al., 2013). This signaling pathway is
almost certainly distinct from the Fyn-dependent microglial
activation pathway, evidenced by the fact that ADAP/ mi-
croglia display unaltered proinflammatory responses (Engel-
mann et al., 2013).
Classical activation of microglia by TLR and TNFR1 ago-
nists produces proinflammatory cytokines and chemokines,
which mediate the downstream effects of microglial activa-
tion. Recently, we showed that TNF directly induces dopa-
minergic neuronal apoptosis (Gordon et al., 2012). In our
present study, the induction of the cytokines IL-6, IL-12, and
TNF was all diminished in Fyn/ and PKC/ microglia
compared with wild-type microglia (Fig. 6A). Consistently,
genetic knockdown of Fyn via siRNA also resulted in dimin-
ished LPS-induced proinflammatory cytokine secretion (Fig.
6B,C). TNF-mediated production of IL-6 and TNF was
also diminished in Fyn-deficient microglia (Fig. 6D,E). Over-
expressing the Fyn Y417A activation loop kinase-deficient
mutant construct in BV2 microglial cells also diminished LPS-
stimulated cytokine production, implicating that the phos-
phorylation of tyrosine 417 is critical to the proinflammatory
function of Fyn (Fig. 6F,G). Furthermore, we showed that the
LPS-induced expression of iNOS and secretion of nitrite were
significantly attenuated in the Fyn/ microglia (Fig. 7A–D).
We and several other groups have reported increased expres-
sion of the NADPH oxidase component gp91phox, as well as
the microglial marker Iba-1 following proinflammatory stim-
ulation of microglia (Gao et al., 2011; Gordon et al., 2011). We
demonstrate herein that prolonged LPS stimulation brought
about the induction of these neuroinflammatory markers in
wild-type, but not in Fyn/ and PKC/ microglia (Fig.
7E,F ).
We extended our in vitro studies to well-characterized an-
imal models of neuroinflammation, wherein a single intra-
peritoneal injection of LPS in mice increases TNF in the
brain to levels that remain elevated long after serum TNF
levels have returned to normal (Qin et al., 2007). We used this
model system to check for LPS-induced striatal proinflamma-
tory cytokine induction in wild-type, Fyn/, and PKC/
mice. Strikingly, a single injection of LPS strongly increased
WT striatal TNF and pro-IL-1 mRNA levels; however, the
induction of these cytokines was greatly diminished in Fyn/
and PKC/ striata (Fig. 8A). In addition to the LPS model,
we also determined the pro-inflammatory role of Fyn in the
well-studied acute MPTP model of neuroinflammation.
MPTP induced reactive microgliosis and increased gp91phox
expression in the nigra of WT mice, but not in Fyn/ mice
(Fig. 8E,F ). Interestingly, a quiescent ramified state of micro-
glial morphology was observed in MPTP-treated Fyn/
mice, whereas more amoeboid activated microglia were noted
in Fyn wild-type mice (Fig. 8C,D). In addition to the MPTP
model, we further used the 6-OHDA-induced selective dopa-
minergic lesion model to validate that ablating Fyn or PKC
confers resistance to nigrostriatal dopaminergic degeneration
and microgliosis (Figs. 9, 10). Together, our results indicate
that the Fyn-PKC signaling axis plays an important role in
mediating the proinflammatory response in both cell culture
and animal models of neuroinflammation.
Recent imaging studies have demonstrated the formation
of glial-neuronal contacts, called gliapses, formed between do-
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paminergic neurons and microglia that precede neuron loss in
the MPTP model (Barcia et al., 2012, 2013). To determine
whether Fyn plays a role in microglial-dopaminergic neuron
contact formation, we adopted the 6-OHDA mouse model.
The formation of gliapses was described recently in the
6-OHDA model (Virgone-Carlotta et al., 2013). Our results
from high-magnification confocal analysis revealed that the
formation of gliapses was almost completely blocked in
6-OHDA-injected Fyn/ mice (Fig. 11). The reduced num-
ber of gliapses correlated well with reduced dopaminergic
neuronal loss following 6-OHDA administration to the
Fyn/mice. Lastly, prolonged stimulation of microglial cells
with inflammogens strongly elicited an induction in Fyn ki-
nase expression levels (Fig. 12). The aggregated form of
-synuclein, the primary component of PD-associated Lewy
bodies, can activate microglia by using CD36- and TLR2-
dependent pathways (Su et al., 2008; Kim et al., 2013a). Stud-
ies are underway in our laboratory to demonstrate the role that
Fyn plays in aggregated -synuclein-induced neuroinflamma-
tory events.
As summarized in Figure 13, we demonstrate that Fyn ac-
tivation plays an upstream regulatory role in eliciting proin-
flammatory signaling following both acute and chronic states
of microglia stimulation. We arrived at this conclusion based
on various lines of experimental evidence from cell culture,
primary culture, and in vivomodels using both Fyn and PKC
knock-out mice. Our mechanistic studies revealed that Fyn
serves as a major upstream regulator of proinflammatory sig-
naling involving PKC, MAP kinase, and the NFB pathways.
Thus, Fyn could be exploited as a potential signaling node in
the development of novel antineuroinflammatory drug candi-
dates for treating PD and other related neurodegenerative dis-
eases with associated microglia-mediated proinflammatory
processes.
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